IP Library Granted Patent US 10,569,097
Granted Patent B2
US 10,569,097 · App. 15/222,243 · Granted Feb 25, 2020

Systems and methods for phototherapeutic modulation of nitric oxide

Inventors: Nicholas William Medendorp, Jr. (Raleigh, NC); Katelyn P. Reighard (Chapel Hill, NC); Gerald H. Negley (Chapel Hill, NC); Nathan Stasko (Chapel Hill, NC)
Assignee: PhotonMD, Inc.
A61N5/0613A61N5/0601A61N5/0603A61N5/0624H01L27/15A61N2005/0611A61N2005/0626A61N2005/0647A61N2005/0652A61N2005/0653A61N2005/0661A61N2005/0662A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,569,097
App. No.
15/222,243
Granted
Feb 25, 2020
Kind
B2
Abstract

Systems and methods for phototherapeutic modulation of nitric oxide in mammalian tissue include use of a first wavelength and first radiant flux of light to stimulate enzymatic generation of nitric oxide, and use of a second wavelength and second radiant flux of light to stimulate release of nitric oxide from endogenous stores of nitric oxide. Pulsed light and/or partially non-overlapping light impingement windows may be used. Non-coherent light impinged on tissue may include a peak wavelength in a range of from 410 nm to 440 nm in the absence of light emissions having a peak wavelength of from 600 nm to 900 nm.

Claims (28)

1. A method of modulating nitric oxide in living mammalian tissue, the method comprising:

impinging light on the tissue, wherein the light impinging on the tissue comprises incoherent light emissions including a first peak wavelength in a range of from 410 nm to 440 nm and a first radiant flux, and wherein the first peak wavelength and the first radiant flux are selected to simulate at least one of (i) enzymatic generation of nitric oxide to increase endogenous stores of nitric oxide or (ii) release of nitric oxide from endogenous stores of nitric oxide,

wherein the light impinged on the tissue is substantially devoid of light emissions having a peak wavelength in a range of from 60- nm to 900 nm.

2. The method of claim 1 , wherein the light impinged on the tissue is devoid of emissions of any wavelength conversion material stimulated by the incoherent light emissions including a first peak wavelength in a range of from 410 nm to 440 nm.

3. The method of claim 1 , wherein the tissue is devoid of an applied or received photosensitive therapeutic compound or agent.

4. The method of claim 1 , wherein at least 65% of a fluence of light impinged on the tissue consists of the incoherent light emissions including a first peak wavelength in a range of from 410 to 440 nm.

5. The method of claim 1 , wherein the light impinged on the tissue is substantially devoid of light emissions having a peak wavelength in a range of from 441 nm to 490 nm.

6. The method of claim 1 , wherein the incoherent light emissions including a first peak wavelength in a range of from 410 nm to 440 nm are provided as a plurality of discrete pulses.

7. The method of claim 1 , wherein the light impinged on the tissue further comprises incoherent light emissions including a second peak wavelength in a range of from 500 nm to 540 nm.

8. The method of claim 7 , wherein the impinging of light on the tissue comprises energizing a first plurality of solid state light emitters distributed among a plurality of multiemitter solid state emitter packages to generate the incoherent light emissions including the first peak wavelength, and energizing a second plurality of solid state light emitters distributed among the plurality of multi-emitter solid state emitter packages to generate the incoherent light emissions including the second peak wavelength.

9. The method of claim 7 , wherein the incoherent light emissions including a first peak wavelength in a range of from 410 nm to 440 nm are impinged on the tissue during a first time window, the incoherent light emissions including a second peak wavelength in a range of from 500 nm to 540 nm are impinged on the tissue during a second time window, and at least a portion of the second time window is non-overlapping with the first time window.

10. The method of claim 9 , wherein an entirety of the second time window is nonoverlapping with the first time window.

11. The method of claim 9 , wherein the second time window is initiated more than one minute after conclusion of the first time window.

12. The method of claim 9 , wherein the light having the first peak wavelength is impinged on the tissue as a plurality of discrete pulses during the first time window, and the light having the second peak wavelength is impinged on the tissue in a steady-state manner not including a plurality of discrete pulses during the second time window.

13. The method of claim 9 , wherein the light having the first peak wavelength is impinged on the tissue in a steady-state manner not including a plurality of discrete pulses during the first time window, and the light having the second peak wavelength is impinged on the tissue as a plurality of discrete pulses during the second time window.

14. The method of claim 1 , wherein the first peak wavelength and the first radiant flux are selected to release nitric oxide from the endogenous stores of nitric oxide.

15. The method of claim 14 , wherein the endogenous stores of nitric oxide comprise nitrosoglutathione, nitrosoalbumin, nitrosohemoglobin, nitrosothiols, nitrosamines, and/or metal nitrosyl complexes in or proximate to the tissue.

16. The method of claim 1 , wherein the tissue comprises at least one of epithelial tissue, mucosal tissue, bone, connective tissue, or muscle tissue, or cervical tissue.

17. The method of claim 1 , wherein the tissue comprises dermal tissue.

18. The method of claim 1 , further comprising:

sensing a temperature condition on or proximate to (a) a therapeutic device arranged to impinge light on the tissue, or (b) the tissue; generating at least one signal indicative of the temperature condition; and controlling impingement of the light on the tissue responsive to the at least one signal.

19. The method of claim 1 , wherein the light impinged on the tissue comprises a fluence of from about 0.5 J/cm2 to about 100 J/cm 2 .

20. The method of claim 1 , wherein the tissue comprises cervical tissue within a body cavity of a patient.

21. The method of claim 1 , wherein the tissue comprises tissue within a body cavity of a patient, and the method further comprises inserting a probe into the body cavity of the patient and prior to the impinging of light on the tissue.

22. The method of claim 1 , wherein the enzymatic generation of nitric oxide is mediated by inducible nitric oxide synthase (iNOS), neuronal nitric oxide synthase (nNOS), and/or endothelial nitric oxide synthase NOS (eNOS) in or proximate to the tissue.

23. The method of claim 1 , wherein the impinging of light on the tissue comprises energizing a plurality of solid state light emitters that is positioned on a flexible substrate, and the method further comprises altering a shape of the flexible substrate to substantially conform to a surface of the tissue.

24. The method of claim 1 , wherein the impinging of light on the tissue comprises energizing a plurality of solid state light emitters that is positioned between the tissue and an ambient light blocking element, and the method further comprises blocking impingement of ambient light on the tissue using the ambient light blocking element.

25. The method of claim 1 , wherein the method is used to reduce or reverse hair loss.

Assignments (7)
SECURITY INTEREST Recorded Dec 2, 2025
From: REVIAN, INC.
To: FP VENTURE DEBT I BETA LTD
Reel/Frame 073090/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2020
From: PHOTONMD, INC.
To: KNOW BIO, LLC
Reel/Frame 052348/0185 →
ENTITY OF CONVERSION Recorded May 19, 2017
From: PHOTONMD, LLC
To: PHOTONMD, INC.
Reel/Frame 042751/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2016
From: KNOW BIO, LLC
To: PHOTONMD, LLC
Reel/Frame 040002/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2016
From: NOVAN, INC.
To: KNOW BIO, LLC
Reel/Frame 039332/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: STASKO, NATHAN; MEDENDORP, NICHOLAS WILLIAM, JR.; NEGLEY, GERALD H.
To: NOVAN, INC.
Reel/Frame 039288/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: REIGHARD, KATELYN P.
To: PHOTONMD, LLC
Reel/Frame 039288/0780 →
Continuity (2)
Provisional Application 62197746 · Jul 28, 2015
Related Publication 20170028215A1 · Feb 2, 2017
Cited By (7)
US 12,347,337 US 12,390,657 US 12,397,169 US 12,440,697 US 12,447,354 US 12,508,439 US 12,702,865